Long Term Data Presented at ESC 2010 Further Support the Benefit of The CYPHER(R) Sirolimus Drug-Eluting Stent Compared to The ENDEAVOR(R) Zotarolimus-Eluting Stent in Important High-Risk Subgroups

Additional Analysis of 18 Month Data of the SORT OUT III Trial Provides Detail on Safety and Efficacy Outcomes in Patients With Diabetes, Acute Coronary Syndrome, or Treatment of Multiple Lesions

STOCKHOLM, September 2, 2010 - Three new analyses of subgroups from the SORT OUT III study
presented at the European Society of Cardiology (ESC) meeting in Stockholm,
Sweden, provide additional detail on longer-term follow-up subgroup safety
and efficacy outcomes in the SORT OUT III trial in three high-risk subgroups
(diabetes, acute coronary syndrome and multiple lesion). These important data
add detail to those already published in the March 2010 issue of The Lancet
on the clinical outcomes for the primary endpoint in the total population and
in multiple subgroups at 9 months follow-up and on clinical outcomes at 18
month follow up of the randomized comparison of the CYPHER(R) Stent and the
Endeavor(R) Stent.

The initial results of the SORT OUT III study were published
in the Lancet and showed significantly reduced adverse events at 9 and 18
months for the CYPHER(R) Sirolimus-eluting Coronary Stent over Medtronic's
Endeavor(R) Stent in an unselected group of 2,332 patients undergoing
coronary intervention in real world clinical practice. The authors reported
that subgroup analysis of the primary endpoint of 9-month Major Adverse
Cardiac Events (MACE, defined as a composite of cardiac death, myocardial
infarction [MI], or target vessel revascularization [TVR]) were also
consistent across all subgroups.

The new data from ESC provide important additional information
on longer-term outcomes at 18 months in three key groups of patients that are
at higher risk of adverse events when undergoing coronary intervention,
namely patients with diabetes, acute coronary syndromes, and treatment of
multiple lesions. These data confirm that the significant reductions in major
adverse events in these subgroups seen at 9 months with the CYPHER Stent
compared to the ENDEAVOR Stent were sustained through 18 months of follow-up
and provide important details of how the components of MACE (death, MI, and
TVR) contribute to the reduction in major adverse events.

Among the high-risk diabetic patient population in SORT OUT III, the
incidence of MACE at 18 months was significantly reduced by 74% with CYPHER
vs. ENDEAVOR (4.8% in the CYPHER Stent group vs. 18.3% in the Endeavor(R)
Stent group; hazard ratio 4.05; 95% confidence intervals: 1.86-8.82). This
difference was driven by statistically significant reductions in death, MI,
TVR and TLR favoring the CYPHER Stent. In the CYPHER Stent group, the
incidence of MACE was also significantly reduced by 46% compared to the
ENDEAVOR Stent in patients without diabetes (4.5% in the CYPHER Stent group
vs. 8.3% in the ENDEAVOR Stent group; hazard ratio 1.87, 95% confidence
intervals: 1.30-2.69).

Among patients with acute coronary syndrome in SORT OUT III (defined as
patients with unstable angina or myocardial infarction), the incidence of
MACE at 18 months was significantly reduced by 43% with CYPHER vs. ENDEAVOR
(5.0% in the CYPHER Stent group vs. 8.7% in the Endeavor(R) Stent group;
hazard ratio 1.78; 95% confidence intervals: 1.10-2.88). This difference was
driven by a statistically significant reduction in TLR and TVR favoring the
CYPHER stent. In the CYPHER Stent group the incidence of MACE was also
significantly reduced by 60% compared to the ENDEAVOR Stent in patients with
stable angina (4.2% in the CYPHER Stent group vs. 10.4% in the ENDEAVOR Stent
group; hazard ratio 2.53, 95% confidence intervals: 1.60-4.02).

Finally, among the high-risk group treated for disease in multiple
lesions in SORT OUT III, the incidence of MACE at 18 months was significantly
reduced by 80% with CYPHER vs. ENDEAVOR (2.6% in the CYPHER Stent group vs.
13.2% in the Endeavor(R) Stent group; hazard ratio 5.29; 95% confidence
intervals: 2.59-10.8). This difference was driven by statistically
significant reductions in death, MI, and TVR favoring the CYPHER Stent. In
the CYPHER Stent group the incidence of MACE was also significantly reduced
by 35% compared to the ENDEAVOR Stent in patients treated for disease in one
lesion (5.4% in the CYPHER Stent group vs. 8.3% in the ENDEAVOR Stent group;
hazard ratio 1.55, 95% confidence intervals: 1.06-2.27).

"The SORT OUT III subgroup analyses further support significant safety
and efficacy differences between the CYPHER(R) Stent and the Endeavor(R)
Stent," said Campbell Rogers, M.D., Chief Scientific Officer and Head, Global
Research and Development, Cordis Corporation and concludes, "In these data
sets, risks of adverse events are up to five-fold higher with the Endeavor(R)
Stent than with the CYPHER(R) Stent in patients with other complications like
diabetes that are described in these data."

Notes to Editors:

About CYPHER(R) Stent

The CYPHER(R) Stent has been chosen by cardiologists worldwide to treat
approximately three million patients with coronary artery disease. The safety
and efficacy of the device is supported by a robust clinical trial program
that includes more than 70 studies that examine the performance of the
CYPHER(R) Stent in a broad range of patients.

About Cordis Corporation

For more than 50 years, Cordis Corporation, a Johnson &
Johnson company, has been a worldwide leader in the development and
manufacture of interventional vascular technology. Through the company's
innovation, research and development, Cordis partners with interventional
cardiologists worldwide to treat millions of patients who suffer from
vascular disease.

*Cordis Corporation has entered into an exclusive worldwide
license with Wyeth for the localized delivery of sirolimus in certain fields
of use, including delivery via vascular stenting. Sirolimus, the active drug
released for the stent, is marketed by Wyeth Pharmaceuticals, a division of
Wyeth, under the name Rapamune(R). Rapamune is a trademark of Wyeth
Pharmaceuticals.

**The third party trademarks used herein are trademarks of
their respective owners.

Contact: Name Ulrike Domany, Director Public Affairs & Communication, (o) +43-1-36-025-310, (m) +43-664-83-504-83